Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Volociximab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine |
| Cohort 2 | EXPERIMENTAL | Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine |
| Name | Type | Description |
|---|---|---|
| Volociximab | DRUG | Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks. |
| Gemcitabine | DRUG | Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment |
Inclusion Criteria: * Male or female, 18 years of age or older. * Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. * May have received prior immunotherapy (including monoclonal antibodies) or vaccine therapies. * Measurable disease, according to RECIST criteria. ...
Top 20 of 68 competitors
Volociximab is an investigational small molecule being studied for the treatment of metastatic pancreatic cancer. It is administered in combination with gemcitabine. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Volociximab is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with pancreatic cancer.
Volociximab is in Phase 2 clinical development for the treatment of metastatic pancreatic cancer. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 2 trial has been completed, and the drug remains under evaluation.
Volociximab has been studied in one clinical trial, identified as NCT00401570. This Phase 2 study evaluated the drug in combination with gemcitabine in patients with metastatic pancreatic cancer. The trial was completed and enrolled 40 participants in the United States and United Kingdom.
Yes, Volociximab is a small molecule drug. It is being investigated as a therapeutic option for pancreatic cancer, specifically in combination with gemcitabine. The drug is in Phase 2 clinical development and is not yet approved for patient use.